title: [PREVENTION OF THE BONES METASTASES OCCURRENCE IN THE PATIENTS WITH RENAL-CELL CANCER].
abstract: Diagnostic significance of estimation of the tartratresistent acid phosphatase (bone TRAP--5b) activity was studied for prognosis of occurrence of metastases in bones (MB) in patients with a renal-cell cancer (RCC). The risk of the MB occurrence was determined in patients after surgical treatment. A skeleton affection rate in patients, to whom zolendronic acid was prescribed, was trustworthy bigger, than such while conduction of treatment. So, application of bisphosphonates is recommended, in particular--zolendronic acid in dosage 4 mg every month under control of the bone TRAP--5b activity with objective of prophylaxis of the MB occurrence in patients, suffering RCC. But, we recommend for the MB diagnosis the method of determination of this marker activity as additional one while examining patients together with standard methods, including osteoscintigraphy, computer tomography.
authors.forename: S I
authors.initials: SI
authors.lastname: Boychuk
authors.forename: A G
authors.initials: AG
authors.lastname: Dedkov
authors.forename: L G
authors.initials: LG
authors.lastname: Yugrinova
mesh_terms: D000135:Acid Phosphatase / Q000235:genetics*; D000368:Aged; D014408:Biomarkers, Tumor / Q000235:genetics*; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000235:genetics / Q000517:prevention & control* / Q000556:secondary / Q000601:surgery; D002292:Carcinoma, Renal Cell / Q000235:genetics / Q000517:prevention & control* / Q000556:secondary / Q000601:surgery; D004164:Diphosphonates / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D005260:Female; D015870:Gene Expression; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D007527:Isoenzymes / Q000235:genetics*; D007680:Kidney Neoplasms / Q000000981:diagnostic imaging / Q000235:genetics / Q000473:pathology / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D011859:Radiography; D000071681:Tartrate-Resistant Acid Phosphatase; D014055:Tomography, Emission-Computed; D016896:Treatment Outcome; D000077211:Zoledronic Acid
chemical_list: D014408:Biomarkers, Tumor; D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D007093:Imidazoles; D007527:Isoenzymes; D000077211:Zoledronic Acid; D000135:Acid Phosphatase; D000071681:Tartrate-Resistant Acid Phosphatase